These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15788540)

  • 1. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude.
    Venkatakrishnan K; Obach RS
    Drug Metab Dispos; 2005 Jun; 33(6):845-52. PubMed ID: 15788540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine.
    Mikami A; Ohtani H; Hori S; Sawada Y
    Int J Clin Pharmacol Ther; 2013 May; 51(5):374-82. PubMed ID: 23357843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.
    Heydari A; Yeo KR; Lennard MS; Ellis SW; Tucker GT; Rostami-Hodjegan A
    Drug Metab Dispos; 2004 Nov; 32(11):1213-7. PubMed ID: 15328252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition.
    VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
    Drug Metab Dispos; 2012 Jan; 40(1):47-53. PubMed ID: 21976621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.
    Gibbs JP; Hyland R; Youdim K
    Drug Metab Dispos; 2006 Sep; 34(9):1516-22. PubMed ID: 16763018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy).
    Van LM; Heydari A; Yang J; Hargreaves J; Rowland-Yeo K; Lennard MS; Tucker GT; Rostami-Hodjegan A
    J Psychopharmacol; 2006 Nov; 20(6):834-41. PubMed ID: 16478752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
    Sauer JM; Long AJ; Ring B; Gillespie JS; Sanburn NP; DeSante KA; Petullo D; VandenBranden MR; Jensen CB; Wrighton SA; Smith BP; Read HA; Witcher JW
    J Pharmacol Exp Ther; 2004 Feb; 308(2):410-8. PubMed ID: 14610241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of prediction methods for in vivo clearance of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride, a dopamine D2 receptor antagonist, in humans.
    Yamazaki S; Toth LN; Black ML; Duncan JN
    Drug Metab Dispos; 2004 Apr; 32(4):398-404. PubMed ID: 15039292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum.
    Subehan ; Usia T; Kadota S; Tezuka Y
    Planta Med; 2006 May; 72(6):527-32. PubMed ID: 16808005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors.
    Wang YH
    Drug Metab Dispos; 2010 Jul; 38(7):1094-104. PubMed ID: 20368327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
    Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
    J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
    Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
    Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
    Reese MJ; Wurm RM; Muir KT; Generaux GT; St John-Williams L; McConn DJ
    Drug Metab Dispos; 2008 Jul; 36(7):1198-201. PubMed ID: 18420781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors.
    Ekins S; Bravi G; Binkley S; Gillespie JS; Ring BJ; Wikel JH; Wrighton SA
    Pharmacogenetics; 1999 Aug; 9(4):477-89. PubMed ID: 10780267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
    Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ
    Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment.
    Venkatakrishnan K; Obach RS; Rostami-Hodjegan A
    Xenobiotica; 2007; 37(10-11):1225-56. PubMed ID: 17968744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
    Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
    Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
    Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
    Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine.
    Zhao SX; Dalvie DK; Kelly JM; Soglia JR; Frederick KS; Smith EB; Obach RS; Kalgutkar AS
    Chem Res Toxicol; 2007 Nov; 20(11):1649-57. PubMed ID: 17907785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm.
    Ito K; Hallifax D; Obach RS; Houston JB
    Drug Metab Dispos; 2005 Jun; 33(6):837-44. PubMed ID: 15897600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.